[Nvidia-backed AI pharmaceutical company Lambic seeks to go public in the U.S. and plans to raise up to $159 million] On October 8, the U.S. biopharmaceutical company Lambic Therapeutics disclosed a prospectus and planned to issue 9.375 million ordinary shares for the first time. The issue price is expected to be $15 to $17 per share, and it plans to raise approximately $141 million to $159 million. Lambic was founded in 2019 and has since raised $461.8 million from investors in the technology and healthcare sectors. Its major shareholders include U.S. investment institutions Catalio Capital Management, Nexus Venture Partners and Coatue, as well as NVIDIA and the investment arm of the Qatar Investment Authority focusing on the medical and health field.